Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterials - Johnson & Johnson

Next Previous
Drug Profile

Research programme: antibacterials - Johnson & Johnson

Alternative Names: ARQ 259034; C6-carbamate ketolides research programme - Johnson & Johnson; DQ-1; JNJ 10275798; JNJ 10278385; JNJ 17069546; JNJ 6333314; JNJ-Q1; MurF inhibitors - Johnson & Johnson; RWJ 670963

Latest Information Update: 04 Nov 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class Fluoroquinolones; Ketolides; Small molecules
  • Mechanism of Action Cell wall inhibitors; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; MurF synthetase inhibitors; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA
  • 31 May 2010 Antimicrobial data from an in vitro study in Bacterial infections released by Johnson & Johnson Pharmaceutical Research & Development
  • 31 May 2010 Preclinical development is ongoing in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top